Saroglitazar, a major PPARα and moderate PPARγ agonist, has also been reported to improve liver enzymes, liver fat content, IR and atherosclerotic dyslipidaemia in participants with NAFLD/NASH (260). Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.